Actos is a diabetes medicine manufactured by Takeda Pharmaceuticals. The diabetes drug Actos is known generically as pioglitazone. Actos was approved for use by the U.S. Food and Drug Administration (FDA) in 1999.
Actos treats type 2 diabetes by targeting the body’s reaction of insulin. Actos works to increase the body’s response to insulin, and in doing so, helps regulate blood sugar levels in type 2 diabetics.
Research data shows that those patients who have been taking Actos for the longest duration of time (more than one year), and those patients who have been prescribed with the highest doses of Actos, are the most susceptible in developing bladder cancer. In fact, patients taking Actos for more than one year have a 40% increased risk of developing bladder cancer, according to this research.
This information regarding the increased risk of bladder cancer from use of Actos comes from a 10-year ongoing cohort study conducted by Takeda Pharmaceuticals, the drug’s manufacturer, and Kaiser Permanente Northern California.
In a similar study conducted by a French health insurance organization and the French Medicines Agency from 2006 – 2009, researchers came to similar conclusions as those discovered by Takeda Pharmaceuticals and Kaiser Permanente Northern California. The French scientists’ data revealed a significant link between the development of bladder cancer and patients using Actos. As a result, in 2011, France and Germany both banned pioglitazone drugs, which includes Actos.
If you or a loved one has taken Actos, and as a result, has experienced an undue amount of suffering due to the development of bladder cancer, you and your loved one may be entitled to receive compensation. For more information about filing an Actos bladder cancer lawsuit, contact an experienced Actos lawyer at Carey Danis & Lowe.
Our lawyers have a wealth of experience in litigating national drug defect lawsuits. We have the knowledge, legal skills, and experience necessary to win an Actos lawsuit against Takeda Pharmaceuticals.
Manufacturer: Takeda Pharmaceuticals
FDA Approval: July 15, 1999 for treatment of type 2 diabetes; controlling blood sugar
Generic Availability: August 17, 2012
Pregnancy Risk: Category C